In the phase 2b study which assessed the efficacy and safety of furmonertinib in patients with EGFR T790M mutated advanced NSCLC, the ORR was 74%, and the mPFS was 9.6 months (95% CI 8.2–9.7) [19]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.